SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-19-014302
Filing Date
2019-12-30
Accepted
2019-12-30 17:09:42
Documents
6
Period of Report
2019-12-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT azrx8k.htm 8-K 52462
2 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION ex3-1.htm EX-3.1 10927
3 FORM OF NOTE PURCHASE AGREEMENT ex10-1.htm EX-10 133262
4 FORM OF SENIOR CONVERTIBLE PROMISSORY NOTE ex10-2.htm EX-10 69982
5 FORM OF WARRANT ex10-3.htm EX-10 48733
6 FORM OF REGISTRATION RIGHTS AGREEMENT ex10-4.htm EX-10 90993
  Complete submission text file 0001654954-19-014302.txt   407905
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 191317239
SIC: 2834 Pharmaceutical Preparations